Findings

What do systematic reviews say?

29 questions · 29 findings · 1 reviews · Oral Health

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 24 · 82.8%Very low 0 · 0%Low 3 · 10.3%Moderate 2 · 6.9%High 0 · 0%

Camomile vs placebo

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Camomile showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.89 [0.62, 1.27]
1 study · 164 participants
GRADE not reported

Sucralfate vs placebo or usual care

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Sucralfate showed no clear difference in oral mucositis (any severity) compared with placebo/usual care (moderate certainty).

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.98 [0.88, 1.1]
3 studies · 222 participants
Moderate

Glutamine vs placebo or usual care

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Glutamine showed no clear difference in oral mucositis (any severity) compared with placebo/usual care; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.78 [0.57, 1.08]
5 studies
GRADE not reported

Low‐level laser therapy vs Placebo or no active treatment

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Laser (low level) showed no clear difference in oral mucositis (any severity) compared with placebo/sham/no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.91 [0.71, 1.17]
5 studies · 234 participants
GRADE not reported

Polaprezinc vs Azulene

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Polaprezinc showed no clear difference in oral mucositis (any severity) compared with azulene; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.82 [0.63, 1.06]
1 study · 31 participants
GRADE not reported

Histamine gel vs placebo

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Histamine gel showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 1.35 [0.91, 1.99]
1 study · 39 participants
GRADE not reported

Chlorhexidine vs placebo/no treatment

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Chlorhexidine showed no clear difference in oral mucositis (any severity) compared with placebo/no treatment (low certainty).

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.76 [0.47, 1.24]
4 studies · 454 participants
Low

Chlorhexidine vs Cryotherapy (ice chips) 60 minutes

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Chlorhexidine showed no clear difference in oral mucositis (any severity) compared with cryotherapy (ice chips); GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 1.03 [0.76, 1.41]
1 study · 133 participants
GRADE not reported

Allopurinol mouthrinse vs placebo/no treatment

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Allopurinol mouthrinse showed no clear difference in oral mucositis (any severity) compared with placebo/no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.77 [0.5, 1.19]
4 studies
GRADE not reported

Intestinal trefoil factor vs placebo

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Intestinal trefoil factor led to lower oral mucositis (any severity) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.52 [0.35, 0.79]
1 study · 99 participants
GRADE not reported

Povidone vs Water

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
no estimate extracted
2 studies
GRADE not reported

Zinc sulphate vs placebo

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Zinc sulphate showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.88 [0.69, 1.11]
1 study · 27 participants
GRADE not reported

Amifostine vs placebo/no treatment

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Amifostine probably leads to lower oral mucositis (any severity) compared with placebo/no treatment (moderate certainty).

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.95 [0.91, 0.99]
3 studies · 430 participants
Moderate

Benzydamine vs placebo

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Benzydamine led to lower oral mucositis (any severity) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.67 [0.47, 0.97]
1 study · 36 participants
GRADE not reported

Traumeel vs placebo

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Traumeel showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.71 [0.49, 1.05]
1 study · 30 participants
GRADE not reported

Prednisone vs placebo

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Prednisone showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 1.03 [0.85, 1.24]
1 study · 66 participants
GRADE not reported

Shenqi-fanghou vs no treatment

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Shenqi-fanghou showed no clear difference in oral mucositis (any severity) compared with no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.9 [0.8, 1]
1 study · 140 participants
GRADE not reported

Propantheline vs placebo

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Propantheline showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.4 [0.12, 1.31]
1 study · 12 participants
GRADE not reported

GM-CSF vs placebo/no treatment

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
no estimate extracted
8 studies
GRADE not reported

Honey vs no treatment

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Honey led to lower oral mucositis (any severity) compared with no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.7 [0.56, 0.88]
3 studies
GRADE not reported